Table 1 Description of the study cohort
Clinical characteristic | n = 177 |
|---|---|
Demographics and anthropometrics | |
Age (years) (median, IQR) | 60 (54–65) |
Sex, male | 107 (60%) |
UNOS race/ethnicity—White | 110 (62%) |
Asian | 20 (11%) |
Black/African American | 15 (8%) |
Hispanic/Latino | 32 (25%) |
Primary underlying etiology | |
Hepatitis C infection (HCV) | 71 (40%) |
Nonalcoholic fatty liver disease (NAFLD) | 30 (17%) |
Alcohol (ARLD) | 19 (11%) |
Biliary-related (PSC/PBC/BC/other) | 18 (10%) |
Autoimmune hepatitis (AIH) | 13 (7%) |
Hepatitis B infection (HBV) | 10 (6%) |
Polycystic liver/kidney disease (PCLD) | 6 (3%) |
Cryptogenic liver disease (CLD) | 3 (2%) |
Other | 7 (4%) |
Comorbidities | |
Co-existing hepatocellular carcinoma (HCC) | 69 (39%) |
Alpha-1 antitrypsin deficiency | 5 (3%) |
Liver disease severity | |
MELD score at LT (median, IQR) | 18 (13–24) |
CTP score at LT (median, IQR) | 9 (7–11) |
Transplant characteristics | |
Living donor | 30 (17%) |
Cold ischemic time (minutes) (median, IQR) | 326 (244–458) |
PRBC transfusion required | 137 (77%) |
PRBC units transfused (median, IQR) | 6 (3–10) |
Post-operative complications | |
Bleeding (≤ 7 days post-LT) | 34 (19%) |
Biliary stricture (≤ 365 days post-LT) | 26 (15%) |
Biliary leak (≤ 365 days post-LT) | 17 (10%) |
Outcomes | |
Readmission to hospital | 93 (53%) |
Readmission to ICU | 50 (28%) |
365 days post-LT all-cause mortality | 6 (3%) |
MDRB and antibiotic usage | |
Peri-operative adjustments to antibiotic regimen | 65 (37%) |
Inpatient days on antibacterial treatment courses (−0.5 to 1 yr post-LT) | 16 (8–33) |
Number of antibacterial agents received (−0.5 to 1 yr post-LT) | 5 (3–7) |
MDRB colonization (≤ 365 days post-LT) | 115 (65%) |
CRE colonization | 31 (18%) |
Ceph-RE colonization | 83 (47%) |
VRE colonization | 77 (44%) |
